Investor Presentation First Nine Months of 2022
25
Investor presentation First nine months of 2022
Novo NordiskⓇ
Novo Nordisk holds solid patent protection, high barriers to
entry, and a collaborative approach to innovation
Novo Nordisk's position is protected
by patents and value chain setup
OZEMPİC
semaglutide injection
RYBELSUS®
semaglutide tablets
Fiasp®
fast-acting insulin aspart
esperoct
turoctocog alfa pegol
Xultophy
insulin degludec/liraglutide
[rDNA origin] injection
EU/US patent
protection1
2031/322
2031/20322,3
20304
2034/322
•
2028/29
•
TRESIBA
2028/29
insulin degludec [rDNA origin] injection
RYZODEG
2028/29
70% insulindegudec and 30% insulin aspart
[rDNA origin injection
refixia®
VICTOZAⓇ
liraglutide injection
2027/28
20235
Barriers to entry for biosimilar players
Research & Development
Need to show comparability in PK/PD trials
Strict regulatory requirements in the EU and the US
Requirement for both drug and device offering
Manufacturing
Economies of scale
Up-front CAPEX requirements with slow return on
investment
Commercialisation
Large and fragmented target audience
Cost pressure from payers
On-going conversion to next-generation drugs and
slow market dynamics
Partnerships and acquisitions support
future R&D
siRNA treatments
Dicerna™
Oral formulations of
therapeutics
Combination
treatments for NASH
GILEAD
Gene editing for
haemophilia
Emisphere seventybio!
Novel treatments for CVD/Rare disease
CORVIDIA
Precision Cardiovascular Therapeutic
of prothena
Heartseed forma
THERAPEUTICS.
1 List does not include all marketed products. 2 Current estimates. WegovyⓇ patent identical to OzempicⓇ patent; 3 Tablet formulation and once-daily treatment regimen are protected by additional patents expiring in 2031-2034; 4 Formulation patent; active
ingredient patent has expired; 5 SaxendaⓇ patent identical to VictozaⓇ patent. PK: Pharmacokinetic, PD: Pharmacodynamic; CAPEX: Capital expenditure; siRNA: Silencing ribonucleic acid; NASH: Non-alcoholic steatohepatitis; CVD: Cardiovascular diseaseView entire presentation